Oncology

The FDA's 2025 biosimilar approvals enhanced treatment options for chronic diseases, improving accessibility and affordability for patients and health care providers.

Discover the vital role of oncology pharmacists in cancer care, exploring their daily challenges, responsibilities, and impact on patient outcomes.

A high-fiber, plant-based diet shows promise in delaying multiple myeloma progression and enhancing metabolism and immune response in patients with precursor conditions.

Tracking your net worth monthly can shift your financial mindset and build lasting wealth.

Fam-trastuzumab deruxtecan-nxki (T-DXd) promises enhanced outcomes for HER2-positive early breast cancer patients post-neoadjuvant treatment.

Pharmacists explore new breast cancer therapies and management strategies, enhancing patient care and treatment outcomes at SABCS.

Ribociclib shows higher early treatment modifications than palbociclib in HR+/HER2– breast cancer, emphasizing the need for proactive toxicity management.

Lessons learned from interprofessional spiritual training and the evolving role of palliative care pharmacists toward an integrated and patient-centric health care system.

A technician-driven workflow implemented in a health system’s specialty pharmacy reduced high-cost oncology drug waste.

New clinical trial results highlight the effectiveness of enfortumab vedotin and pembrolizumab in improving survival for patients with muscle-invasive bladder cancer.

The rise of intravesical therapies in non–muscle invasive bladder cancer underscores the vital role of pharmacists in advancing patient care.

A UK research team has pioneered a blood test using infrared technology to detect lung cancer cells, promising earlier diagnoses and personalized treatments.

FDA approves Rybrevant Faspro, a groundbreaking subcutaneous therapy for EGFR-mutated lung cancer, enhancing patient comfort and survival rates.

The approval was supported by findings from the TRITON3 trial, which enrolled certain patients with metastatic castration-resistant prostate cancer (mCRPC).

Patients learn the importance of understanding treatment-related skin issues, recognizing symptoms, and adopting gentle skincare practices for better management.

This review examines the mechanisms of therapy, summarizes the existing literature, and highlights the evolving treatment options for unresectable hepatocellular carcinoma.

Biosimilars are set to revolutionize oncology by enhancing access and affordability while maintaining safety and efficacy.

Discover how GLP-1 receptor agonists may benefit breast cancer patients by promoting weight loss and improving long-term health outcomes.

ctDNA analysis revolutionizes cancer treatment by predicting responses, detecting resistance, and monitoring minimal residual disease in patients.

FDA grants a national priority voucher to teclistamab and daratumumab for relapsed/refractory multiple myeloma, enhancing treatment approval speed.

Second-line and later treatment options for synovial sarcoma are limited. Afamitresgene autoleucel is the first FDA-approved T-cell receptor therapy, demonstrating long-lasting responses and tolerable adverse effects in pretreated patients.

Explore the latest insights on breast cancer treatment, focusing on radiation, endocrine therapy, and the role of pharmacists in patient care.

The approval is supported by findings from the phase 3 DESTINY-Breast09 trial.

New findings at SABCS reveal MammaPrint's role in identifying early-stage breast cancer patients who benefit from anthracyclines, reducing unnecessary treatment.

Research reveals that isatuximab on-body injector shows consistent safety and efficacy across various body weight groups in multiple myeloma treatment.

SABCS 2025 showcases breakthroughs in breast cancer therapy, emphasizing novel therapies and precision medicine to enhance patient outcomes.